At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 245 enrolled
Drug / intervention
Arimoclomol +1 moredrug
Likely dose
Arimoclomol 124 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
In Brief
A Phase 3 clinical trial evaluating Arimoclomol and Placebo for Amyotrophic Lateral Sclerosis. Completed, enrolled 245 participants across 29 sites in 12 countries.
Detailed Summary
A multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of arimoclomol in amyotropic lateral sclerosis (ALS)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesBelgium, Canada, France, Germany, Italy, Netherlands, Poland, Spain, Sweden, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartJul 2018
Primary CompletionDec 2020
TodayJul 2026
First PostedApr 9, 2018
Enrollment StartJul 31, 2018
Primary CompletionDec 18, 2020
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 8.2 years ago
Interventions
Arimoclomoldrug
2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily
Placebodrug
2 matched placebo capsules taken 3 times daily